Riddle MC, et al. - In this randomized, single-masked, two-way crossover, inpatient study, researchers examined the pharmacodynamic impacts of the amylin analog pramlintide and insulin delivered in a fixed ratio over a 24-hour period. Change in mean glucose by continuous glucose monitoring was the primary outcome measure. In patients with type 1 diabetes, co-administration of fixed-ratio pramlintide and regular human insulin for 24 hours was found to improv postprandial hyperglycemia and glycemic variability. During use of pramlintide, gastrointestinal side effects were more frequent. However, no major hypoglycemic events were noted with pramlintide or placebo.